Medicilon(SH:688202) Xin Lang Cai Jing·2026-01-09 06:53Group 1 - The core viewpoint of the news is that Meidi Xi's stock price increased by 5%, reaching 71.16 CNY per share, with a trading volume of 369 million CNY and a turnover rate of 4.00%, resulting in a total market capitalization of 9.561 billion CNY [1] - Meidi Xi is a biopharmaceutical company based in Shanghai, established on February 2, 2004, and listed on November 5, 2019, primarily providing comprehensive new drug research and development services for pharmaceutical companies and other new drug research institutions [1] - The company's main business revenue composition includes preclinical research at 50.34%, drug discovery and pharmaceutical research at 49.64%, and other (supplementary) at 0.01% [1] Group 2 - From the perspective of fund holdings, one fund under Wan Jia Fund has a significant position in Meidi Xi, with the Wan Jia Guo Zheng 2000 ETF holding 99,500 shares, accounting for 0.54% of the fund's net value, making it the second-largest holding [2] - The Wan Jia Guo Zheng 2000 ETF was established on June 29, 2022, with a current scale of 1.286 billion CNY, and has achieved a return of 4.84% this year, ranking 1511 out of 5509 in its category [2] - The fund manager, Yang Kun, has a tenure of 6 years and 80 days, with the fund's total asset scale at 13.868 billion CNY, achieving the best return of 81.38% and the worst return of -32.3% during his tenure [2]